

1                                   **The Amyloid Precursor Protein is a conserved Wnt receptor**

2   Tengyuan Liu<sup>1,2</sup>, Maya Nicolas<sup>2,3,4,#</sup>, Tingting Zhang<sup>1,2</sup>, Heather Rice<sup>3,4,#</sup>, Alessia Soldano<sup>3,4,#</sup>,  
3   Annelies Claeys<sup>3,4</sup>, Iveta M. Petrova<sup>5</sup>, Lee G. Fradkin<sup>5</sup>, Bart De Strooper<sup>3,6</sup>, and Bassem A.  
4   Hassan<sup>1\*</sup>

5   <sup>1</sup>Paris Brain Institute – Institut du Cerveau, Sorbonne Université, Inserm, CNRS, Hôpital Pitié-  
6   Salpêtrière, Paris, France.

7   <sup>2</sup>Doctoral School of Biomedical Sciences, KU Leuven, Leuven, Belgium

8   <sup>3</sup>Center for Brain and Disease, VIB, Leuven, Belgium

9   <sup>4</sup>Center for Human Genetics, University of Leuven School of Medicine, Leuven, Belgium

10   <sup>5</sup>Laboratory of Developmental Neurobiology, Department of Molecular Cell Biology, Leiden  
11   University Medical Center, Leiden, The Netherlands

12   <sup>6</sup>UK Dementia Research institute at University College London (UCL), United Kingdom

13   <sup>#</sup>Present addresses:

14   H.R.: Department of Biochemistry and Molecular Biology, Oklahoma Center for Geroscience &  
15   Heathy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

16   A.S.: Laboratory of Translational Genomics, Department of Cellular, Computational and  
17   Integrative Biology (CIBIO), University of Trento, Trento, Italy

18   M.N.: School of Sciences and Engineering, The American University in Cairo, Cairo, Egypt

19   \*Corresponding author: Bassem A. Hassan ([bassem.hassan@icm-institute.org](mailto:bassem.hassan@icm-institute.org))

20   Key words: Brain Development, Axon growth, Amyloid Precursor Protein, Wnt, *Drosophila*,  
21   mouse cortical neurons

22

23 **SUMMARY**

24 The Amyloid Precursor Protein (APP) and its homologues are transmembrane proteins required  
25 for various aspects of neuronal development and activity, whose molecular function is unknown.  
26 Specifically, it is unclear whether APP acts as a receptor, and if so what its ligand(s) may be. We  
27 show that APP binds the Wnt ligands Wnt3a and Wnt5a and that this binding regulates APP protein  
28 levels. Wnt3a binding promotes full length APP (flAPP) recycling and stability. In contrast, Wnt5a  
29 promotes APP targeting to lysosomal compartments and reduces flAPP levels. A conserved  
30 Cysteine Rich Domain (CRD) in the extracellular portion of APP is required for Wnt binding, and  
31 deletion of the CRD abrogates the effects of Wnts on flAPP levels and trafficking. Finally, loss of  
32 APP results in increased axonal and reduced dendritic growth of mouse embryonic primary cortical  
33 neurons. This phenotype can be cell-autonomously rescued by full length, but not CRD-deleted,  
34 APP.

35

## 36 INTRODUCTION

37 The Amyloid Precursor Protein (APP) is the precursor that generates the A $\beta$  peptide, whose  
38 accumulation is associated with Alzheimer's disease (AD)[1]. As an ancient and highly conserved  
39 protein, APP and its homologs are found across animal species in both vertebrates and  
40 invertebrates[2]. As a result of the alternative splicing of the 18 exons coding for APP, there are 3  
41 major isoforms expressed in different organs or tissues in mice and human[3]. APP695 is the major  
42 isoform expressed in the brain[4]. The expression of APP is detected at early stage during  
43 development[5,6]. In the developing mouse cortex APP mRNA is expressed continuously starting  
44 at embryonic day 9.5 coinciding with the initiation of neurogenesis and neuronal differentiation  
45 [7].

46 Structurally, APP is a type I transmembrane protein, which possesses a large extracellular amino  
47 acids sequence, an  $\alpha$ -helix transmembrane sequence and a relatively short intracellular C-terminal  
48 sequence[8,9]. Based on the architecture of the ectodomain, APP has been proposed to be a  
49 putative receptor [10–14]. APP trafficking and processing have been intensively studied ever since  
50 the protein was first cloned. The turnover of transmembrane full length APP is rapid[15,16], and  
51 internalised APP can be degraded in lysosome or processed by  $\alpha$ -,  $\beta$ - and  $\gamma$ -secretase in different  
52 subcellular compartments to produce corresponding segments of APP. [17,18]. Recently, effort  
53 has been put into researching the function of the proteolytic products of APP under normal  
54 physiological condition[19], as this may provide new clues for AD research.

55 During *Drosophila* brain development the fly homolog of APP, called APPL, functions as key  
56 component of the neuronal Wnt-PCP signaling pathway and regulates the axonal outgrowth in fly  
57 mushroom body[20]. Both mammalian APP and fly APPL contain a Cysteine Rich Domain(CRD)  
58 in the ectodomain of APP which resembles the CRD of the binding domain of the Wnt Tyrosine-  
59 protein kinase receptor Ror2[9,21], suggesting the intriguing possibility that APP may itself be a  
60 receptor for Wnt family member.

61 Wnt signalling is an evolutionary conserved signal transduction pathway that regulates a large  
62 number of cellular processes. Three Wnt signaling pathway have been well described: the  $\beta$ -  
63 catenin based canonical pathway, the planar cell polarity (PCP/Wnt) signaling pathway and the  
64 calcium pathway. Wnt signaling regulates various features during development such as cell

65 proliferation, migration and differentiation[22]. Recently, increasing evidence indicates that the  
66 Wnt signaling pathways are involved in the APP related A $\beta$  production[23,24], but the precise  
67 mode of interaction between APP and the various Wnt pathways remains unclear.

68 The presence of CRD in APP, the reported involvement of Wnt signaling in APP processing and  
69 the importance of Wnt signaling during development suggested to us that APP may be a novel  
70 class of Wnt receptor regulating neuronal development. We used *Drosophila* and mouse  
71 embryonic primary cortical neurons as models to explore the APP-Wnt interactions during  
72 development. We provide evidence that the CRD of APP is a conserved binding domain for both  
73 canonical and PCP Wnt ligands. Furthermore, APP trafficking and expression is regulated by Wnts  
74 through the CRD, which in turn is required for APP to regulate axonal and dendritic growth and  
75 branching.

76

## 77 RESULTS

### 78 *Drosophila* APP Like interacts genetically with Wnt5

79 *Drosophila* APPL has been implicated in neural development[25,26] and is required for learning  
80 and memory [27]. *Drosophila* APPL shares high sequence homology with human APP and has  
81 been used as a model for understanding the physiological function of the APP family [28,29]. We  
82 previously reported that *appl* genetically interacts with components of the Wnt-PCP pathway [20]  
83 during mushroom body (MB) axon growth. The MBs are a bilateral neuronal structure in the fly  
84 brain required for learning and memory[30]. To understand the role of APPL in axonal PCP  
85 signaling, we first explored the specific nature of the genetic interaction between *appl* and the gene  
86 encoding the PCP protein Van Gough (Vang). In contrast to control MBs, 17% of male *appl* null  
87 mutant flies (*appl*<sup>d/Y</sup>, henceforth Appl<sup>-/-</sup>) displayed a loss of the MBb-lobe (Figure 1A, A'). The  
88 PCP receptor Vang is also required for  $\beta$ -lobe growth [31]; we observed that flies homozygous for  
89 the null allele *vang*<sup>stbm-6</sup> exhibited 50%  $\beta$ -lobe loss. Whereas *vang*<sup>stbm-6</sup> heterozygotes show no MB  
90 defects, the loss of one copy of *vang* in Appl<sup>-/-</sup> flies is comparable (43%  $\beta$ -lobe loss) to the  
91 complete loss of *vang* (Figure 1B). Therefore, in the absence of *appl*, *vang* is haploinsufficient.  
92 Next, we performed rescue experiments of Appl<sup>-/-</sup> mutant flies. Re-expression of APPL in the  
93 mutant MBs significantly rescued  $\beta$ -lobe loss. In contrast, the overexpression of Vang in Appl<sup>-/-</sup>  
94 null flies failed to do so. These loss and gain of function data suggest that Wnt-PCP signaling  
95 requires APPL to regulate axonal growth (Figure 1B).

96 APPL and Vang are both transmembrane proteins that are part of the same receptor complex  
97 required for MB axonal growth [20]. We wondered if APPL interaction with the Wnt-PCP pathway  
98 involved a ligand and focused on *Drosophila* Wnt5 as a candidate. Wnt5 has been implicated in  
99 the regulation of MB axon growth [29,32] although the mechanism is unclear. We first examined  
100 the genetic interaction between *Wnt5* and *vang* in  $\beta$ -lobe axon growth. Loss of *vang* caused a  
101 highly penetrant phenotype (50%), while *Wnt5* nulls showed  $\beta$ -lobe loss only in 5% of the brains  
102 examined, suggesting that *Wnt5* is largely dispensable for  $\beta$ -lobe growth. Surprisingly, *Wnt5*<sup>-/-</sup>;  
103 *vang*<sup>-/-</sup> double mutants showed an almost complete rescue of *vang* loss of function (Figure  
104 1Ca,b,d,D, Table S1). Therefore, in the absence of Vang, *Wnt5* inhibits  $\beta$ -lobe growth, suggesting  
105 that *Wnt5* interacts with another receptor and antagonizes its function in PCP-mediated axon  
106 growth. We therefore examined the genetic interaction between *Wnt5* and *appl*. Loss of *Wnt5* in

107 Appl<sup>-/-</sup> flies resulted in a phenotype similar to Appl<sup>-/-</sup> flies alone (Figure 1Cb,c,e, E). Thus, in the  
108 absence of APPL, Wnt5 no longer negatively impacts MB axon growth, suggesting that APPL  
109 may be a Wnt5 receptor.

110

### 111 **APPL and human APP bind Wnt5 via the Cysteine Rich Domain**

112 Wnt5 is a member of the large family of Wnt ligands, some of whose receptors and co-receptors  
113 harbor a conserved extracellular Cysteine Rich Domain (CRD) thought to be important for Wnt  
114 binding[33,34]. Intriguingly, APP harbors a CRD-like domain[35]in its extracellular region that  
115 includes 12 cysteine residues conserved across APP paralogs and orthologs (Figure 2A). The  
116 distribution of the cysteine residues resembles those present in the CRDs of other PCP receptors  
117 such as Fz and Ror-2 (Figure S1). We asked whether the CRDs of APP and APPL are potential  
118 Wnt5a-binding domains. To test this, we generated forms of human APP (hAPP) and APPL  
119 lacking the CRD (hAPP $\Delta$ CRD and APPL $\Delta$ CRD). Next, we overexpressed a tagged form of Wnt5a  
120 together with hAPP, APPL, hAPP $\Delta$ CRD or APPL $\Delta$ CRD in HEK293 cells and performed co-  
121 immunoprecipitation(IP) assays. Wnt5a immunoprecipitated full-length hAPP and APPL but not  
122 hAPP $\Delta$ CRD or APPL $\Delta$ CRD (Figure 2B). Reciprocally, full-length hAPP and APPL  
123 immunoprecipitated significant amounts of Wnt5a in contrast to hAPP $\Delta$ CRD and APPL $\Delta$ CRD  
124 (Figure 2B'). Similarly, APPL was found to precipitate Wnt5 from transfected *Drosophila* S2 cell  
125 lysates (Figure S2).

126

### 127 **Wnt5a treatment affects APP trafficking and expression in maturing mouse primary** 128 **cortical neuron**

129 The findings above suggest that the APP family may represent a new class of conserved Wnt  
130 receptors. We sought to investigate this further at a cell biological level using developing mouse  
131 embryonic primary cortical neurons as a model system. APP trafficking and processing have been  
132 intensively investigated in studies relating to AD, and according to early reports the half-life of  
133 APP is quite short, ranging from 1 hour to 4 hours [36,37]. In mouse embryonic (E16) primary  
134 neuron cultures, full-length mouse APP (fl-mAPP; henceforth we refer to mouse APP as mAPP  
135 and to human APP as hAPP) expression significantly dropped after 2 hours of treatment with

136 translational inhibitor (Cycloheximide) (Figure S3), suggesting relatively rapid turnover of mAPP.  
137 To study the relation between mAPP and Wnts we first verified that mAPP also binds Wnt5a  
138 through its CRD and found that fl-mAPP but not mAPP $\Delta$ CRD coIP's with Wnt5a, similar to APPL  
139 and hAPP (Figure 3A). Next, we used immunofluorescence to localize mAPP with or without  
140 Wnt5a treatment in developing cortical neurons during axonal outgrowth (DIV7). mAPP is  
141 modified to maturation in the Trans Golgi Network (TGN) to be subsequently transferred to the  
142 plasma membrane where it can be internalized into early endosomes. From the early endosome,  
143 mAPP is either recycled back to the TGN through retromer-dependent sorting, or to the late  
144 endosome and then lysosome to be degraded [17,38]. We used markers for early endosomes  
145 (Rab5), TGN (Golgin97) and lysosomes (Lamp1) to trace mAPP trafficking after Wnt5a treatment.  
146 As shown in the Figure 3 (B, C), compared to control, the fraction of mAPP co-localizing with  
147 early endosomes was not affected by Wnt5a treatment, indicating normal initial internalization of  
148 mAPP. However, we found less mAPP in the TGN, and more mAPP in lysosomes (Figure 3B, D,  
149 E) suggesting that Wnt5a regulates intracellular targeting of mAPP after internalization.  
150 Importantly, the levels of expression of these markers (Rab5 Golgin97 and Lamp1) are not affected  
151 by Wnt5a treatment (Figure S4). Next, we asked if this altered trafficking affected mAPP levels.  
152 We found that the level of fl-mAPP was significantly reduced after 4hrs of Wnt5a, as shown by  
153 western blot (Figure 3F, G), with no effect on mAPP mRNA levels (Figure 3 H). The results of IF  
154 and WB suggest that the decrease of the mAPP upon Wnt5a treatment is caused by lysosomal  
155 degradation. To confirm this, we used Bafilomycin-A in combination with Wnt5a treatment to  
156 inhibit the lysosome and found that this restored mAPP to control levels (Figure 3 I-L). These data  
157 suggest that non-canonical Wnt5a-PCP signaling reduces mAPP stability.

158

### 159 **Wnt3a binds to and stabilizes APP via the CRD**

160 We wondered whether mAPP can also bind other members of the Wnt family of ligands. Wnt3a  
161 is one of the 19 Wnt members in mouse and human. During development Wnt3a usually induces  
162  $\beta$ -catenin signaling pathway which plays an import role in gene expression, cell proliferation and  
163 differentiation [39,40]. Recent studies suggest that Wnt3a and beta-Catenin signaling may be  
164 involved in AD pathology [41,42]. More interestingly, studies on mouse AD models showed that  
165 Wnt3a and Wnt5a interact competitively and antagonistically with regards to APP-mediated

166 synapse loss [23,24]. We therefore wondered whether, like Wnt5a, Wnt3a also binds to mAPP  
167 through the conserved CRD and regulates its levels. To test this, we performed IP experiments  
168 with Wnt3a. We found that fl-mAPP and Wnt3a co-IP in a CRD-dependent fashion (Figure 4A).  
169 We next tested the effects of Wnt3a treatment on APP trafficking. As shown in Figure (4 B, C),  
170 the fraction of mAPP colocalized with early endosomes was not affected. However, more mAPP  
171 was present in the TGN compared to controls (Figure4 B, D), with no effect on the lysosomal  
172 mAPP fraction (Figure4 B, E). The expression levels of Rab5, Golgin97 and Lamp1 are not  
173 affected after Wnt3a treatment (Figure S4). Western blot analysis showed increased fl-mAPP upon  
174 Wnt3a treatment (Figure4 F, G), but no effect on mRNA levels (Figure4 H). There is evidence that  
175 mAPP is recycled back to the TGN from early endosomes through the retrograde pathway[38]. To  
176 test whether Wnt3a regulates mAPP retrotrafficking to the TGN, we co-treated primary neurons  
177 with Wnt3a and a retromer inhibitor (LY294002). This reversed the effect of Wnt3a on mAPP  
178 trafficking protein levels (Figure4 I-L). Finally, we tested the effects of simultaneous treatment  
179 with Wnt3a and Wnt5a. This resulted in no change to APP protein levels compared to controls,  
180 suggesting that Wnt3a and Wnt5a neutralize each other's effects on mAPP (Figure4 M, N), again  
181 with no effects on mRNA levels (Figure4 O). Taken together, these data indicate that Wnt3a also  
182 binds to mAPP via the CRD and regulates mAPP trafficking and expression and that Wnt5a and  
183 Wnt3a act antagonistically to regulate APP protein homeostasis.

184

### 185 **The CRD is required for Wnt-mediated regulation of APP trafficking and expression**

186 Our data thus far show that APP interacts with Wnts through its CRD and that Wnts regulate APP  
187 intracellular trafficking and expression. We therefore asked whether the CRD is required for the  
188 effects of Wnts on mAPP. To address this question, we created two lentiviral vectors: pLv-pSyn1-  
189 mAPP-Flag-IRES-eGFP (flag-tagged fl-mAPP) and pLv-pSyn1-mAPP $\Delta$ CRD-Flag-IRES-eGFP  
190 (flag-tagged mAPP $\Delta$ CRD). Primary cortical neurons from APP knockout mice were transduced  
191 with the fl-mAPP or mAPP $\Delta$ CRD vectors, or a control GFP vector (pLv-pSyn1-IRES-eGFP)  
192 exogenous APP/APP $\Delta$ CRD could be well detected using either anti-APP or anti-flag antibodies  
193 (Figure S5 A-C). Virus induced APP/APP $\Delta$ CRD expression level was on average slightly lower  
194 than endogenous (Figure S5 B, C) which is largely explained by ~50% transduction efficiency  
195 (data not shown). In neurons transduced with wild type mAPP we confirmed that mAPP expression



196 could be increased and decreased by Wnt3a and Wnt5a treatments, respectively (Figure5 A,C). In  
197 contrast, in neurons transduced with mAPP $\Delta$ CRD those effects were eliminated (Figure5 B,D).  
198 Finally, we performed IF to trace mAPP and mAPP $\Delta$ CRD localization. Neurons transduced with  
199 wild type mAPP showed the same results as wild type neurons with more mAPP in the TGN upon  
200 Wnt3a treatment and more mAPP in lysosomes upon Wnt5a treatment (Figure S6 A-D). In  
201 contrast, neurons transduced with mAPP $\Delta$ CRD neither Wnt3a, nor Wnt5a treatment showed a  
202 significant effect on mAPP localization to early endosomes, TGN or lysosomes compared to  
203 controls (Figure5 E-H). In summary, these data show that the CRD of mAPP is critical for  
204 Wnt3a/5a binding and mediates the effects of Wnts on mAPP trafficking and expression.

205

### 206 **CRD is critical for APP to regulate neurite outgrowth and complexity**

207 APP and its proteolytic products have been reported to affect neurite outgrowth during  
208 development [43,44] in different systems. We used primary cortical neuron derived from E16.5  
209 mice embryos to investigate if the CRD of mAPP is required for regulation of neurite outgrowth  
210 by mAPP. We examined axonal and dendritic outgrowth (Figure 6A) at three developmental  
211 stages *in vitro*: DIV2, DIV3 and DIV7[45].

212 While we found no effect on initial outgrowth at DIV2 (Figure S7A-F), at DIV3 mAPP knockout  
213 neurons exhibit increased axonal outgrowth compared to controls reflected in three parameters:  
214 total axon length, longest axon length and the number of branch tips (Figure 6B-E). In contrast,  
215 dendritic outgrowth was not different from controls (Figure S8A-C). We asked whether the CRD  
216 was required for mAPP function during neurite outgrowth. To this end we transfected mAPP  
217 knockout neurons with either fl-mAPP or mAPP $\Delta$ CRD. Increased axonal length and axonal  
218 branch tips were rescued by the fl-mAPP but not by the form lacking the CRD at DIV3 (Figure  
219 6B-E). Next, we analysed axonal branching in greater detail and found that loss of mAPP increased  
220 the numbers of both primary and secondary axonal branches at DIV3, an increase that was rescued  
221 by fl-mAPP but not by mAPP $\Delta$ CRD (Figure 6F,G). Finally, we examined the Axon Complexity  
222 Index (ACI) [46], which measures the ratio of branches of different orders to total branch number,  
223 at DIV3. At this early stage, the ACI showed a tendency to increase in mAPP knockout neurons  
224 that was not significant (Figure S8D), likely because both primary and secondary branches show

225 a similar level of increase. Together these data suggest an overall increase in axonal growth. In  
226 contrast to axonal growth, we found no significant alterations in dendritic length or branching  
227 (Figure S8E-G) consistent with the fact that the spur in dendritic outgrowth is largely initiated at  
228 DIV4[47,48].

229 To further analyse neurite outgrowth, we examined axonal and dendritic growth at DIV7. By this  
230 stage mAPP knockout neurons showed an increased ACI (Figure 7A,B). In contrast, total axonal  
231 length, longest axon length and the total number of branch tips was not significantly different  
232 (Figure 7C-E). The increase in axonal complexity in mAPP knockout neurons was due to a  
233 significant reduction in the number of primary branches and a significant increase in the number  
234 of secondary branches (Figure 7F,G). Once again, all phenotypes were rescued by fl-mAPP but  
235 not mAPP $\Delta$ CRD.

236 Finally, we examined dendritic growth at DIV7. We observed no difference in total dendrite length  
237 or the size of the longest dendrite (Figure S9A,B), but observed a significant decrease in the total  
238 number of dendritic processes in mAPP knockout neurons compared to controls (Figure S9C).  
239 This reduction was due to the presence of fewer main dendritic processes in mAPP knockout  
240 neurons but no effect was observed on the primary or secondary dendritic branches (Figure S9D-  
241 F). All phenotypes were rescued by fl-mAPP but not mAPP $\Delta$ CRD. Taken together, our results  
242 show that the role of APP in neuronal maturation requires the CRD domain.

243

244 **DISCUSSION**

245 Here we identify a previously-unknown conserved Wnt receptor function for APP proteins. We  
246 show that APP binds both canonical and non-canonical Wnt ligands via a conserved cysteine rich  
247 domain and that this binding regulates the levels of full length APP by regulating its intracellular  
248 trafficking from early endosomes to the trans Golgi network versus the lysosome. Finally, we show  
249 that APP through the CRD regulates neurite growth and axon branching complexity in primary  
250 mouse cortical neurons

251 APP has been extensively reported to be involved in regulating neurite outgrowth [43,44,49–52],  
252 with conflicting conclusions as to whether APP promotes or inhibits neurite outgrowth. In our  
253 experiments, we found that while in *Drosophila* APPL loss reduced axonal growth, the comparison  
254 of axonal outgrowth and branching in primary cortical neuron derived from mAPP wild type or  
255 mAPP knock out mice at DIV2, DIV3 and DIV7 showed that loss of mAPP significantly  
256 accelerated axonal maturation. Specifically, we found that the initial phase of axonal growth at  
257 DIV2 is unaffected, but that APP mutant axons grow longer at DIV3 and then show increased axon  
258 complexity at DIV7. We therefore suggest that the conflicting data in the literature may arise from  
259 examining different types of neurons at different time points, where the requirement of APP may  
260 differ in a context-specific manner. We speculate that this context specificity may in part be due  
261 to the levels and types of Wnt ligands present in the environment.

262 Finally, our findings suggest that in addition to the well described proteolytic processing of APP,  
263 the regulation of its recycling by Wnt ligands may be crucial for its function. It is important to note  
264 that, like proteolytic processing, Wnt ligands regulate APP stability post-translationally, as we  
265 found no effect on APP mRNA levels upon Wnt treatment. With regards to the role of APP  
266 processing in Alzheimer's disease, recently published work suggests that an imbalance between  
267 Wnt3a/canonical signaling pathway and the Wnt5a/PCP signaling pathway at the initial step of  
268 amyloid beta production could trigger a vicious cycle favouring the amyloidogenic processing of  
269 APP [23,24]. We suggest that our data provide a mechanistic framework for understanding how  
270 this may occur in neurons.

271

272 **ACKNOWLEDGMENTS**

273 We thank Dr. Radoslaw Ejsmont for writing the co-localization macro, Natalia Danda for the  
274 construction of the plasmids used in this work, Drs. Ariane Ramaekers, Natalia Mora Garcia, Gerit  
275 Linneweber, Simon Weinberger and Guangda Liu for helpful discussions. We thank Drs. Zeynep  
276 Kalender Atak and Marina Naval Sanchez for support on the statistical analysis of the data and Dr.  
277 Jean-Maurice Dura for fly lines. Mouse breeding work was conducted at the PHENO-ICMice  
278 facility. The Core is supported by 2 Investissements d’Avenir grants (ANR-10- IAIHU-06 and  
279 ANR-11-INBS-0011-NeurATRIS) and the “Fondation pour la Recherche Médicale”. Primary  
280 neuron culture work was carried out at the CELIS core facility with support from Program  
281 Investissements d’Avenir (ANR-10-IAIHU-06). Light microscopy was carried out at the  
282 ICM.Quant facility. We thank all core technical staff involved. This work was supported by ICM,  
283 the program “Investissements d’avenir” ANR-10-IAIHU-06, the Einstein-BIH program, the Paul  
284 G. Allen Frontiers Group, and the Roger De Spoelberch Foundation (BAH), the Vlaams Instituut  
285 voor Biotechnologie (VIB; BAH and BDS), the Methusalem grants from KU Leuven (BDS and  
286 BAH), Fonds Wetenschappelijke Onderzoeks (FWO) grants G.0543.08, G.0680.10, G.0681.10  
287 and G.0503.12 (BAH), the Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO;  
288 ZonMw TOP grant 40-00812-98-10058) and the Hersenstichting Nederland [HS 2011(1)-46]  
289 (LGF), grant “projet ARC n° SFI20121205950” from the Association pour la Recherche sur le  
290 Cancer (ARC, JMD) and a doctoral fellowship from the Centre National de Recherche Scientifique  
291 Libanais (LCNRS, MN). Tengyuan Liu and Tingting Zhang are funded by the Chinese Scholarship  
292 Council (CSC). The authors declare no competing financial interests.

293

294 **AUTHOR CONTRIBUTIONS**

295 The authors have made the following declarations about their contributions: Conceived and  
296 designed the experiments: Tengyuan Liu, Tingting Zhang, Maya Nicolas, Lee G. Fradkin and  
297 Bassem A. Hassan. Performed the experiments: Tengyuan Liu, Tingting Zhang, Maya Nicolas,  
298 Heather Rice, Alessia Soldano, Annelies Claeys, Iveta M. Petrova and Jean-Maurice Dura.  
299 Analyzed the data: Tengyuan Liu, Tingting Zhang, Maya Nicolas, Heather Rice, Bart De Strooper,

300 Lee G. Fradkin, and Bassem A. Hassan. Wrote the paper: Tengyuan Liu, Maya Nicolas, and  
301 Bassem A. Hassan. All authors read and approved the manuscript

302

### 303 **Declaration of Interests**

304 The authors declare no competing interests.

305

### 306 **Materials and Methods**

#### 307 **Drosophila stocks and maintenance**

308 Flies were raised at 25°C, on standard cornmeal and molasses medium. The stocks used in this  
309 study are: w\*, Appl<sup>d</sup>; Vang<sup>stbm-6</sup>; w1118, Wnt5<sup>400</sup>; P247Gal4; w\*, Appl<sup>d</sup>, Wnt5<sup>400</sup>.

#### 310 **Cloning**

311 All constructs were generated by PCR amplification and overlap extension PCR. PCR products  
312 were inserted into the respective vectors by classical restriction enzyme cloning. All constructs  
313 were sequence-verified. To generate transgenic flies, open reading frames with epitope tags were  
314 cloned into the pUAST-attB fly expression vector and transgenes were inserted into the genome  
315 at the VK37 docking site (2L, 22A3) via PhiC31-mediated transgenesis.

#### 316 **Mushroom body analyses**

317 Adult fly brains were dissected in phosphate buffered saline (PBS) and fixed in 3.7% formaldehyde  
318 in PBT (PBS+ 0.1% Triton100-X) for 15 min. Then, the brains were washed 3 times in PBT and  
319 blocked in PAX-DG for 1 hr at RT. The samples were later incubated with the primary antibody  
320 overnight at 4°C. After incubation, the brains were washed 3 times with PBT and incubated with  
321 an ALEXA Fluor® secondary antibodies (Life technologies) for 2 hr at RT. After 3 times washes  
322 in PBT, the brains were mounted in Vectashield (Vector Labs, USA) mounting medium. The  
323 following antibodies were used: mouse anti-FasII (Developmental Studies Hybridoma Bank  
324 (DSHB), 1/50), rabbit anti- GFP (Invitrogen, 1/500), rat anti-Cadherin (DSHB, 1/100). The  
325 mounted brains were imaged on a LEICA DM 6000 CS microscope coupled to a LEICA CTR

326 6500 confocal system and a Nikon A1-R confocal (Nikon) mounted on a Nikon Ti-2000 inverted  
327 microscope (Nikon). The pictures were then processed using ImageJ

### 328 **Primary cortical neuron culture, virus transduction and plasmids transfection**

329 The animal experiments were carried out in accordance with animal welfare regulations and have  
330 been approved by Ethic Committee and French regulatory authorities of the respective institutes.  
331 APP knock out mice were a gift from the De Strooper lab. Cortical primary neuron cultures were  
332 prepared from embryonic day 16.5 mice (APP wild or APP mutant), as described previously[53].

333 Virus (pLv-pSyn1-mAPP-Flag-IRES-eGFP, pLv-pSyn1-mAPP  $\Delta$  CRD-Flag-IRES-eGFP or pLv-  
334 pSyn1- eGFP) transduction was performed during seeding in 24 well plates( $4 \times 10^5$  cells/mL). 50uL  
335 (50uL par well) of the adequate lentiviral dilution in the medium of interest must be ready in tubes.  
336 Seed 150uL of the cell preparation to each well. Immediately add 50ul of the diluted lentiviral  
337 preparation to each well(final MOI 2). Mix slowly the cells-lentivirus suspension by pipetting.  
338 Incubate 1h at 37°C. Finally add 800uL of culture medium to each well and incubate for 3  
339 additional days before any analysis.

340 Plasmids (pLv794\_pTrip\_PromSynaptin1\_GFP\_DeltaU3, pLv-pSyn1-MmApp-FLAG-IRES-  
341 eGFP or pLv-pSyn1-mAPP  $\Delta$  CRD-FLAG-IRES-eGFP) transfection was performed at the onset  
342 of cell seeding ( $4 \times 10^5$  cells/mL) in 24 wells plates with coverslip coated with PDL 24hour before.  
343 All procedure follow the protocol from Lipofectamine 3000 transfection reagent (Thermofisher  
344 Catalog Number: L3000008) with little modified, each well transfection with 500ng corresponding  
345 plasmid, medium was refreshed 5-6 hours after transfection.

### 346 **Wnt and inhibitor treatment in primary neuron**

347 Wnt5a(400ng/ml)(645-WN-010, R&D Systems), Wnt3a(150ng/ml)(1324-WNP-010, R&D  
348 Systems) and PBS/BSA(control) addition performed at Div 7. In all experiments related to  
349 inhibitor, cells will be treated with inhibitor 1hour after Wnt addition(Bafilomycin A1(100nM,  
350 invivogen, 88899-55-2), LY294002(10uM, Sigma, L9908)-as wnt3a or wnt5a treatment could  
351 affect APP protein expression clearly 2 hours later (Figure S10)- and a DMSO (0.05%DMSO in  
352 culture medium) group will be set as control. Protein or RNA samples collected after 4hours Wnt  
353 treatment.

### 354 **Quantitative real-time PCR (qRT-PCR)**

355 Cells were lysed for RNA or protein extraction and then subjected to qRT-PCR or western blot as  
356 previously described [54]. The detailed sequence of each primer used in the whole study for qRT-  
357 PCR was summarized below :  $\beta$ -actin, sense 5'- TCCATCATGAAGTGTGACGT-3' and anti-  
358 sense 5'- GAGCAATGATCTTGATCTTCAT -3', mAPP, sense 5'-  
359 CATCCAGAACTGGTGCAAGCG-3' and anti-sense 5'- GACGGTGTGCCAGTGAAGATG -3'  
360 GAPDH, sense 5'- GCTGCCAAGGCTGTGGGCAAG-3' and anti-sense 5'-  
361 GCCTGCTTCACCACCTTC -3'.

### 362 **Western Blots**

363 Western blots was performed follow the user guide of Mini Gel Tank (ThermoFisher, A25977)  
364 with little modified. Briefly, Protein samples collected from total cell lysates with RIPA buffer,  
365 supernatant were collected after centrifugation, denatured samples were loaded separated on the  
366 4-12% polyacrylamide gels (SDS-PAGE)( ThermoFisher, NW04122BOX) and then transfered to  
367 the 0.42um nitrocellulose membranes, blots visualization performed after primary and secondary  
368 antibody incubation.

### 369 **Immunoprecipatation**

370 HEK293 cells in 10cm dish (70% confluent) were transfected with pCDNA3-MmApp-FLAG-  
371 IRES-eGFP , pCDNA3-mAPP  $\Delta$  CRD-FLAG-IRES-eGFP, pCDNA3-Wnt5a-myc, pCDNA-  
372 Wnt3A-V5 or co-transfected APP or APP  $\Delta$  CRD with Wnt3a or Wnt5a. 3 days after transfection,  
373 cells were collected with NP-40 lysis buffer, then sample supernatant was collected after >12000  
374 rpm centrifugation for 20min at 4 degree, 450ul supernatant was incubated with primary antibody  
375 overnight at 4 degree, then Protein G sepharose beads(Thermo Fisher Scientific) were added to the  
376 sample to capture protein-antibody complex by rotating 2 hours at room temperature, then washed  
377 four times with the lysis buffer, and resuspended with loading buffer then denatured at 95 degree  
378 for 10 mins, blots visualized after western blot procedure as described before.

### 379 **Immunofluorescence**

380 At DIV 7, cultured primary neurons in 24 wells were washed once with 1X PBS, then fixed in 4%  
381 paraformaldehyde (PFA) in PBS at room temperature (RT) for 10 minutes. After 3 times washing  
382 with 1X PBS, cells were blocked with 10% normal donkey or goat serum in 1 X PBS for 30  
383 minutes at RT followed by 3 times washing in 1 X PBS. Thereafter, cells were incubated with

384 primary antibodies diluted in 1 X PBS containing 1% normal donkey or goat serum for 2-3 hours  
385 at RT. 3 times washing with 1 X PBS, incubated with appropriate secondary antibodies conjugated  
386 with Alexa Fluor 488, Alexa Fluor 555, or Alexa Fluor 647 (1:500, Invitrogen) in 1 X PBS  
387 containing 1% normal donkey or goat serum for 1 hours at RT. Washed with 1 X PBS for 3 times,  
388 then counterstained the slides with DAPI (1:2000, Sigma) and mounted by using Vectashield  
389 (Vector) after rinsing. Primary antibodies used in this study were rabbit anti-APP (1:100, Synaptic  
390 Systems, 127 003), mouse anti-rab5 (1:100, Synaptic Systems, 108011), mouse anti- Golgin-97  
391 (1:100, Invitrogen, A-21270), rat anti-Lamp1 (1:20, Santa Cruz, sc-19992). After staining, images  
392 were obtained by using confocal microscope (Olympus FV-1200 or Leica SP8). The percentage  
393 of APP or APP- $\Delta$ CRD co-localizing with rab5, Golgin-97 and Lamp1 was calculated using  
394 JACOP [55] via an automated macro that was written in house.

### 395 **Statistical analyses**


396 Statistical analyses were performed using GraphPad Prism software (GraphPad Software Inc., La  
397 Jolla, CA, USA). Differences between groups were compared using the G-test, One-way ANOVA  
398 and Mann Whitney two-sample test (two-tail) as appropriate.

399




# Figure 1

## APPL mediates Wnt5a function in axonal growth




## Figure 2

### APPL and Wnt5 interact via the APP Cysteine Rich Domain




## Figure 3 Wnt5a regulates APP expression through changing its intracellular trafficking




## Figure 4

### Wnt3a binds to and regulates APP expression through changing its intracellular trafficking




## Figure 5


### CRD is required for Wnt3a/5a to affect APP trafficking and expression



## Figure 6 Cysteine Rich Domain is critical for APP to regulate neurite outgrowth at DIV3



## Figure 7 Cysteine Rich Domain is critical for APP to regulate neurite outgrowth and complexity at DIV7



400 **Figure legends**

401 **Figure 1: APPL mediates Wnt5a function in axonal growth**

402 (A-A') Structure of the MB neurons in adult wild type and APPL<sup>-/-</sup> mutant flies.  
403 Immunofluorescence using anti-FascilinII (FasII) antibody that labels the axons of the MB. (A) In  
404 wild type brains, the axons of the MB project dorsally to form the  $\alpha$  lobe and medially to form the  
405  $\beta$  lobe. (A') In APPL null mutant flies (APPL<sup>d/Y</sup> referred to as APPL<sup>-/-</sup>) there is axonal growth  
406 defect of the  $\beta$  lobe (as indicated by the asterisk) in 17% of the brains examined (n=97). Images  
407 are z-projections of confocal image stacks (scale bar, 50  $\mu$ m). (B) APPL and VanG synergistically  
408 interact and APPL is necessary for VanG activity. The histogram shows the percentage of the  $\beta$   
409 lobe defect in different genetic backgrounds. The loss of Vang induced a significantly higher  
410 penetrant phenotype up to 50%, (n=103) compared to APPL<sup>-/-</sup>; *p* value = 5.18<sup>-7</sup> calculated with G-  
411 test. The loss of one copy of Vang in wild type background had no effect on axonal growth (n=30).  
412 However, the removal of one copy of Vang in APPL<sup>-/-</sup> background significantly increased the  
413 phenotype to 43% (n=47) compared to APPL<sup>-/-</sup>; *p* value = 0.001026. The penetrance of the latter  
414 phenotype was not significantly different from the one observed in Vang<sup>-/-</sup>; *p* value = 0.4304. While  
415 the overexpression of APPL rescued the APPL<sup>-/-</sup> phenotype (4%, n=54); *p* value = 0.01307, the  
416 overexpression of Vang failed to (21%, n=52); *p* value = 0.4901. \* Indicates a *p* value<0.05. Data  
417 are shown as median  $\pm$  whiskers. (Ca-e) Immunofluorescence analysis using anti-FasII antibody  
418 to show the structure of the MB axons in adult mutant flies of the following genotypes: (a) Vang<sup>-/-</sup>  
419 <sup>-/-</sup>, (b) Wnt5<sup>-/-</sup>/Y referred to as Wnt5<sup>-/-</sup>, (c) APPL<sup>-/-</sup>, (d) Wnt5<sup>-/-</sup>,Vang<sup>-/-</sup> and (e) Wnt5<sup>-/-</sup>,APPL<sup>-/-</sup>. Images  
420 are z-projections of confocal image stacks (scale bar, 20  $\mu$ m). The asterisks correspond to the  $\beta$   
421 lobe loss phenotype. (D) Wnt5 inhibits axonal growth, after branching, independently of Vang.



422 The Histogram shows the percentage of the  $\beta$  lobe loss phenotype.  $Vang^{-/-}$  flies exhibit a highly  
423 penetrant phenotype of 50% (n=104), while  $Wnt5^{-/-}$  flies show a significantly less penetrant  
424 phenotype (5%, n=103);  $p$  value =  $2.33^{-14}$  calculated with G-test. The loss of  $Wnt5$  rescued  $Vang$   
425 loss of function (6%, n=98);  $p$  value =  $4.56^{-12}$ . (E)  $Wnt5$  inhibits axonal growth probably through  
426 APPL. Histogram showing the penetrance of the  $\beta$  lobe loss phenotype. In  $APPL^{-/-}$  flies, 18% of  
427 the brains tested showed an axonal defect (n=106). This percentage did not significantly change in  
428 the absence of both  $Wnt5$  in  $APPL^{-/-}$  flies (21%, n=86);  $p$  value = 0.6027. \*\*\* indicates a  $p$  value <  
429  $1^{-5}$ .

430

### 431 **Figure 2: APPL and Wnt5 interact via the APP Cysteine Rich Domain**

432 (A) APPL extracellular region contains a conserved CRD. The figure shows a CLUSTAL  
433 alignment of the CRD of different APP homologs. The 12 cysteine residues (as indicated by the  
434 red asterisks) are highly conserved across species. (B-B')  $Wnt5a$  binds APPL and APP in a CRD  
435 dependent manner. (B) Co-immunoprecipitation (co-IP) of the full-length proteins APP-flag and  
436 APPL-flag but not their truncated forms  $APP^{\Delta CRD}$ -flag and  $APPL^{\Delta CRD}$ -flag with  $Wnt5a$ -myc. (B')  
437 Reciprocal co-IP showing that  $Wnt5a$ -myc is co-IPed with flAPP-flag and APPL-flag can but not when the  
438 CRDs are deleted.

439

### 440 **Figure 3: Wnt5a regulates APP expression through changing its intracellular trafficking**

441 (A) Co-immunoprecipitation (co-IP) of  $Wnt5a$ -Myc with full-length proteins mAPP-flag or  
442 mAPP-delatCRD-flag. The tagged proteins were co-expressed in HEK293T cells and  
443 immunoprecipitated with anti-flag or anti-Myc antibody, wild type mAPP pulled down  $Wnt5a$  and

444 vice versa, while mAPP lacking the CRD showed impaired ability to pull down Wnt5a even with  
445 higher protein levels compared to wild type mAPP in the input. (B) mAPP localization after 4  
446 hours PBS/BSA or Wnt5a treatment. Immunofluorescence using antibodies to APP, Rab5 (early  
447 endosome marker) Golgin97 (TGN marker) or Lamp1 (lysosome marker) to reveal mAPP  
448 localization in different intracellular compartments, the inset shows a high magnification image of  
449 the area in the white box and arrows indicate the overlap of mAPP with respective cellular  
450 compartment marker. (C-E) Quantification of the overlap between mAPP and early endosome  
451 TGN or lysosome respectively after Wnt5a treatment. (F) mAPP protein expression is altered after  
452 Wnt5a treatment, Western blotting for mAPP and Actin was done on lysates from DIV7 primary  
453 cortical neurons. (G) Quantification of the Western blot result for fig F. (H) *mAPP* mRNA is not  
454 affected after Wnt5a treatment, qPCR for *mAPP* and *actin* was done in mRNA sample from DIV7  
455 primary cortical neurons, *APP*<sup>-/-</sup> mice derived primary neurons were used as a negative control.  
456 (I-J) The lysosome inhibitor Bafilomycin rescues Wnt5a-induced mAPP reduction in mAPP  
457 protein levels. (I) untreated controls. (J) Cells treated with the Bafilomycin. (K-L) Quantification  
458 of the western blot result for fig(I-J). Bars represent the mean±s.e.m. for at least three independent  
459 experiments. 40-50 cells from at least two independent experiments were analyzed for each group.  
460 \*P<0.05, \*\*P<0.01. Scale bar = 10um.

461

462 **Figure 4: Wnt3a binds to and regulates APP expression through changing its intracellular**  
463 **trafficking**

464 (A) Co-immunoprecipitation (co-IP) of Wnt3a-V5 with full-length proteins mAPP-flag or mAPPL  
465 ΔCRD. The tagged proteins were co-expressed in HEK293T cells and immunoprecipitated with  
466 ant-flag or anti-v5 antibody, wild type mAPP pulled down Wnt3a and vice versa, while mAPP

467 lacking the CRD showed impaired ability to pull down Wnt3a even with higher protein levels  
468 compared to wild type mAPP in the input. (B) mAPP localization after 4 hours PBS/BSA or Wnt3a  
469 treatment. Immunofluorescence using antibodies to APP, Rab5, Golgin97 or Lamp1 to reveal  
470 mAPP localization in different intracellular compartments, the inset shows a high magnification  
471 image of the area in the white box and arrows indicate the overlap of mAPP with respective cellular  
472 compartment marker. (C-E) Quantification of the overlap between mAPP and early endosome,  
473 TGN or lysosome, respectively, after Wnt3a treatment. (F) mAPP protein expression after Wnt3a  
474 treatment. Western blotting for mAPP and Actin was done on lysates from DIV7 primary cortical  
475 neurons. (G) Quantification of the Western blot results for fig F. (H) *mAPP* mRNA is not affected  
476 after Wnt3a treatment, qPCR for *mAPP* and *actin* was done in mRNA sample from DIV7 primary  
477 cortical neurons, *APP*<sup>-/-</sup> mice derived primary neurons were used as a negative control. (I-J) The  
478 Retromer inhibitor Ly294002 rescues Wnt3a-induced increase in mAPP expression levels (I)  
479 untreated controls. (J) Cells treated with Ly294002. (K-L) Quantification of the Western blot result  
480 for fig(I-J). (M-O) Wnt5a and Wnt3a working in a competing way on affecting mAPP protein  
481 expression. (M) Western blot performed with cell lysate from the DIV7 primary cortical neuron  
482 treated with Wnt3a and Wnt5a at the same time for 4 hours, PBS/BSA group act as control group.  
483 (N) Quantification of the Western blot result for fig M. (O) qPCR results of mAPP knockout  
484 neurons (negative control) and PBS/BSA or Wnt3a+Wnt5a treated neurons. Bars represent the  
485 mean±s.e.m. for at least three independent experiments. 40-50 cells from at least two independent  
486 experiments were analyzed for each group. \*P<0.05, \*\*P<0.01. Scale bar = 10um.

487

#### 488 **Figure 5: CRD is required for Wnt3a/5a to affect APP trafficking and expression**

489 (A-D) CRD is critical for Wnt3a/5a regulation of mAPP protein expression. (A-B) APP knock-out

490 primary cortical neuron expressing exogenous wild type or CRD mutant mouse APP via lenti-  
491 virus transduction were treated with Wnt3a or Wnt5a at DIV7, 4 hours later protein samples were  
492 collected for Western blots. Wnt3a upregulated fl-mAPP and Wnt5a downregulated mAPP (A), in  
493 contrast both Wnt3a or Wnt5a failed to affect mAPP $\Delta$ CRD expression (B). (C-D) quantification  
494 of the Western blots results for figure A and B respectively. (E-H) Routing of mAPP trafficking  
495 by Wnt3a/5a requires the CRD. (E) Localization of exogenous mAPP in APP knock-out primary  
496 cortical neurons after 4 hours of Wnt3a or Wnt5a treatment. Immunofluorescence using antibodies  
497 to APP, Rab5 (early endosome marker) Golgin97 (TGN marker) or Lamp1 (lysosome marker) to  
498 reveal mAPP localization in different intracellular compartments, the inset shows a high  
499 magnification image of the area in the white box and arrows indicate the overlap of mAPP with  
500 respective cellular compartment marker. (F-H) Quantification of the overlap between mAPP and  
501 early endosome, TGN, or lysosome, respectively, after Wnt3a or Wnt5a treatment. Bars represent  
502 the mean $\pm$ s.e.m. for at least three independent experiments. 40-50 cells from at least two  
503 independent experiments were analyzed for each group. \*P<0.05, Scale bar = 10um.

504

505 **Figure 6: Cysteine Rich Domain is critical for APP to regulate neurite outgrowth at DIV3.**

506 (A) Schematic of a primary neuron, colored lines indicate axonal or dendritic branch tips which  
507 were quantified, yellow indicates the Axon Initial Segment (AIS) marked with Ankyrin G in  
508 experiments (B) Representative confocal images primary cortical neurons of the four genotypes  
509 examined: mAPP wild type, mAPP knock out and mAPP knock-out rescue with APP or CRD-  
510 mutant APP. Transfection of plasmid containing GFP alone, mAPP-flag-GFP or mAPP $\Delta$ CRD-  
511 flag-GFP performed at the onset of cell seeding. Cells were fixed at DIV3 and immunolabeled  
512 with GFP, AnkG. (C-E). Quantification of three parameters from the four primary neuron

513 genotypes at DIV3. (C) Quantification of the total axon length (the main axonal process and the  
514 branches deriving from the main process) at DIV3 (D) Quantification of the length of longest  
515 axonal process at DIV3. (E) Quantification of the total axonal branch tips at DIV3. (F)  
516 Quantification of primary branch tips at DIV3. (G) Quantification of secondary branch tips at  
517 DIV3. 50-60 cells from at least two independent experiments were analyzed for each group.  
518 \*P<0.05, \*\*P<0.01 \*\*\*p<0.001, Scale bar = 50um.

519

520 **Figure 7: Cysteine Rich Domain is critical for APP to regulate neurite outgrowth and**  
521 **complexity at DIV7**

522 CRD is required for APP to regulate axon branching complexity at DIV7. (A) Representative  
523 confocal images showing primary cortical neurons of the four genotypes examined: mAPP wild  
524 type, mAPP knock out and mAPP knock-out rescued with APP or CRD-mutant APP. Transfection  
525 of plasmid containing GFP alone, mAPP-flag-GFP or mAPP $\Delta$ CRD-flag-GFP performed at the  
526 onset of cell seeding. Cells were fixed at DIV7 and immunolabeled with GFP, AnkG. (B) Analysis  
527 of Axon complexity Index (ACI) at DIV7. (C) Quantification of the total axonal length at DIV7.  
528 (D) Quantification of the length of longest axonal process at DIV7. (E) Quantification of the all  
529 axonal branch tips at DIV7. (F) Quantification of primary branch tips at DIV7. (G) Quantification  
530 of secondary branch tips at DIV7. 50-60 cells from at least two independent experiments were  
531 analyzed for each group. \*P<0.05, \*\*P<0.01 \*\*\*p<0.001, Scale bar = 100um

532

# Supplementary-Figures

**Table S1**  
**Genetic interaction between Wnt5 and Vang**

| <b>Genotype</b>                          | <b>N</b> | <b><math>\beta</math> loss</b> |
|--|----------|--------------------------------|
| Vang <sup>-/-</sup>                      | 104      | 49.5%                          |
| Wnt5 <sup>-/-</sup>                      | 103      | 4.5%                           |
| Wnt5 <sup>-/-</sup> ;Vang <sup>-/-</sup> | 98       | 6.45%                          |
| Wnt5 <sup>-/-</sup> ;Vang <sup>-/+</sup> | 80       | 6.15%                          |
| Wnt5 <sup>-/+</sup> ;Vang <sup>-/-</sup> | 92       | 52.1%                          |

## Figure S1

### PCP receptors harbor conserved Cysteine Rich Domains (CRD)

**A**

```
Fz 1 -----YDQSPLDASPHYRSGGGLMASSGTELDGLPHHNRCEPITISICKNIPY 48
fz 1 VRAQAAGQVSGPGQQAPPPQP-QQSG---QQYNGERGISIPDHGYCQIPISIPLCDIAY 56
      :*: * . * :*: . * . . :*: * * :*: * * :*: * *
Fz 49 NMTIMPNLIGHTKQEEAGLEVHQFAPLVKIGCSDDLQLFLCSLYVVPVCTILERPIPPGRS 108
fz 57 NQTIMPNLLGHTNQEDAGLEVHQFYPLVKVQCSAELKFFLCSMYAPVCTVLEQALPPCRS 116
      * *****:***:***:***** * * * : * * : * : * * * : * . * * * : * * * *
Fz 109 LCESAR-VCEKLMKTYNFWPENLECSKFPVHGEDLCAENTSSASTAATPTRSVAKV 167
fz 117 LCERARQCCEALMNKFGFQWPDTLKCEKFPVHGAGELCVGQNTSDKGTPTPSLLEPFWTS 176
      ** * * * * * : * : * : * : * : * : * : * : * : * : * : * : * : * : * : *
Fz 168 T-----TRKHQTGVESPHRNIGFVCPVQLKTPLGMGYELKVGKDLHDCGAPCHAM-- 218
fz 177 NPQHGGGGYRGGYPGGAGTVERGKFSRPRALRVPSYLNHFHFL----GEKDCGAPCEPTKV 232
      . * . . * * * * * * * * * * * * * * * * * * * * * * * * * * * *
Fz 219 ----FFPERERTVLR-- 229
fz 233 YGLMYFGPEELRFSRTW 249
      : * . * . *
```


**B**

```
Ror-2 1 ----- 0
Ror 1 EVEDSEAITLQPDGPDSPPLTLKGYFLNLEPWNITIVQGQTALHCKVAGNPPPNV 60
Ror-2 1 -----NSLNAIEE-----P 9
Ror 61 RWLKNDAVVOEPRRVIIRKTEYGSRLRIQDLDTDTGYYQCVATNGLKTITATGVLYVR 120
      * . * : * *
Ror-2 10 VTRRH-HQRHHEREREENGYCAPYSCKVKCEYLTVGQVWYSLEDPTGGWKNEQVTTA-LWD 67
Ror 121 LGPHTSPNHNFDQDDQEDGFCQPYRGIACARFIGNRTIYVDSLQMCGEIEENRITAAFTMI 180
      : * : * : * : * : * : * : * : * : * : * : * : * : * : * : *
Ror-2 68 ELISDLTGLCREAAEKMLCAYAFFNCHMEGGRAVKAPLCFEDCQATHLQFCYNDWVLIIE 127
Ror 181 GTSTQLSDQCSQFAIPSFCHFVFPFLCDARSRAPKPRELCRDECEVLENDLCRQEYTIARS 240
      : * : * : * : * : * : * : * : * : * : * : * : * : * : * : *
Ror-2 128 KKERNMFIKSRGHFRLPNCSSLPNHNAMRRPNCYSYIGLTELKESVSYDCRNNGRNFYM 187
Ror 241 NPLIL-----MRLQPKCEALPMPE-SPDAANCMRIGIPAERL-GRYHQCYNGSGADYR 292
      : * : * : * : * : * : * : * : * : * : * : * : * : * : * : *
Ror-2 188 GTMNVSKSGIPCQRWDTQYPHKHFQPPPLVFHQLLEGENYCRNAGGEEHPWPCYTVDESVR 247
Ror 293 GMASTTKSGHCQPWALQHPHSHRLSSTPELGGGHAYCRNPGQVEGPPWCFTQNKVR 352
      * . . : * * * * * * * * * * * * * * * * * * * * * * * * * * * *
Ror-2 248 WQHCDIPMCPDYVDFNAVDLNTPIKMEKFFTPSM 281
Ror 353 VELCDVPPCSPRDGSKMG----- 370
      : * * : * * *
```



## Figure S2

### Co-immunoprecipitation assays reveal that *Drosophila* APPL binds to WNT5




## Figure S3

### Rapid turn over of fl-mAPP in culture mouse primary cortical neurons


*DIV 7 primary neuron from E16.5 embryo cortex (A+/+ c57 pregnant mouse )*

Protein sample collected after 0.5, 1, 2, 4hours DMSO(0.05%) or CHX(50ug/ml) treatment



## Figure S4


### Rab5 Golgin97 and Lamp1 expression are not affected after Wnt3a/5a treatment




## Figure S5

### Lenti-virus induced exogenous APP expressed in APP knock out primary cortical neuron


A



B




C




## Figure S6

### Lenti-virus induced exogenous APP interacts with Wnts in knock out primary cortical neuron




## Figure S7

### Neurite outgrowth is unaffected in APP knock out neurons at Div2




## Figure S8

### Analysis of dendritic outgrowth and axon complexity index at DIV3



## Figure S9 Outgrowth and complexity analysis of neurite at DIV7







533 **Summary of Supplemental Material**

534 **Table S1: Genetic interaction between Wnt5 and Vang**

535 The table lists the penetrance of the phenotype and the number of brains analyzed in the Vang-  
536 Wnt5 genetic interaction experiment.

537

538 **Figure S1: PCP receptors harbor conserved Cysteine Rich Domains (CRD)**

539 CLUSTAL alignment of the extracellular regions of Drosophila Frizzled (Fz) and Mus musculus  
540 Firzzled-1 (Fz-1) (A). CLUSTAL alignment of the extracellular regions of Drosophila Ror-2 and  
541 Mus musculus Ror-2 (Ror)(B). All proteins showed conserved cysteine residues in their  
542 extracellular region (as indicated by the red asterisks).

543

544 **Figure S2: Co-immunoprecipitation assays reveal that Drosophila APPL binds to WNT5.**

545 S2 cells were transfected in triplo with the indicated expression plasmids, lysates prepared and V5-  
546 tagged WNT5-containing complexes were immunoprecipitated with anti-V5 antisera. Following  
547 SDS-PAGE and transfer to PVDF membrane, MYC-tagged APPL species were detected with anti-  
548 MYC and an HRP-conjugated chemiluminescent detection reagent

549

550 **Figure S3: Rapid turn over of fl-mAPP in culture mouse primary cortical neurons.**

551 (A-B) Time course (0.5h, 1h, 2h, 4h) of fl-mAPP expression after Cycloheximide(50ug/ml) or  
552 DMSO(0.05%) treatment at DIV7. (C-D) Quantification of fl-mAPP expression after  
553 Cycloheximide or DMSO treatment. Bars represent the mean $\pm$ s.e.m. for at least two independent  
554 experiments. \*\*P<0.01, \*\*\*\*P<0.0001

555

556 **Figure S4: Rab5 Golgin97 and Lamp1 expression after Wnt3a/5a treatment.**

557 (A) Protein expression of fl-mAPP Rab5 Golgin97 and Lamp1 after 4hours Wnt3a/5a treatment at  
558 DIV7. (B-E) Quantification of fl-mAPP Rab5 Golgin97 and Lamp1 after Wnt3a/5a treatment. Bars  
559 represent the mean±s.e.m. for at least two independent experiments. \*P<0.05, \*\*P<0.01

560

561

562 **Figure S5: Lenti-virus induced exogenous mAPP expressed in mAPP knock out primary**  
563 **cortical neuron**

564 (A) Figures in middle and left panel shows mAPP protein induced by lenti-virus pLv-pSyn1-  
565 mAPP-Flag-IRES-eGFP or pLv-pSyn1-mAPP Δ CRD-Flag-IRES-eGFP respectively could be  
566 detected by immunofluorescence, right panel is a negative control which transduced with pLv-  
567 pSyn1-IRES-eGFP. (B-C) Exogenous mAPP could be detected by western blot with anti-flag or  
568 anti-APP antibody. scale bar = 10um

569

570 **Figure S6: Lenti-virus induced exogenous interact with Wnts in mAPP knock out primary**  
571 **cortical neuron**

572 (A-D) Interaction between exogenous wild type mAPP with Wnts (A) location of exogenous  
573 mAPP in APP knock-out primary cortical neurons After 4 hour Wnt3a or Wnt5a treatment.  
574 Immunofluorescence using antibody app with rab5(early endosome marker) golgin97(TGN  
575 marker) or lamp1(lysosome marker) to reveal mAPP location in different intracellular  
576 compartment, the inset fig with White arrow is a high zoom in of the area in white box, arrow  
577 indicate the overlap of mAPP with relative cellular compartment. (B-D) quantification of the  
578 overlap between mAPP and early endosome TGN or lysosome respectively after Wnt3a or Wnt5a  
579 treatment. \*P<0.05. scale bar = 10um.

580

581 **Figure S7: Neurite outgrowth is unaffected in APP knock out neurons at Div2**

582 Loss of mAPP barely affect neurite outgrowth at DIV2. (A-C) Quantification of total axon length,  
583 longest axon length and axon branch tips from DIV2 cultured primary cortical neuron. (D-F)  
584 Quantification of total dendrite length, longest dendrite length and dendrite branch tips from Div2

585 cultured primary cortical neuron. Bars represent the mean±s.e.m. for each group, at least two  
586 independent experiments, n=50-60.

587

588 **Figure S8: Analysis of dendritic outgrowth and axon complexity index at DIV3**

589 APP mutant barely changes dendrite development at DIV3. (A-C) Quantification of (A) total  
590 dendrite length, (B) longest dendrite length and (C) dendrite branch tips from DIV3 cultured  
591 primary cortical neuron. (D) Axon complexity Index (ACI) analysis of axon in DIV3 of APP-WT  
592 APP-KO and APP-KO with rescue. (E-G) Quantification of (E) main dendrite process, (F) primary  
593 and (G) secondary dendrite process numbers.

594

595 **Figure S9: Outgrowth and Complexity analysis of neurite at DIV7**

596 (A-C) Quantification of (A) total dendrite length, (B) longest dendrite length and (C) dendrite  
597 branch tips from DIV7 cultured primary cortical neuron. (D-F) Quantification of (D) main dendrite  
598 process, (E) primary and (F) secondary dendrite process numbers from DIV7 cultured primary  
599 cortical neuron. \*\*\*\*P<0.0001

600

601 **Figure S10: Time course of fl-mAPP after Wnt3a/5a treatment**

602 Representative western blot for the time course (0.5h, 1h, 2h, 4h) of fl-mAPP expression after  
603 PBS/BSA (ctrl) and Wnt3a/5a treatment at DIV7. Relative expression value of the protein bands  
604 normalized to the respective actin were also shown

605

606 **Reference**

- 607 1. Selkoe, D.J., and Hardy, J. (2016). The amyloid hypothesis of Alzheimer's disease at  
608 25 years. *EMBO Mol. Med.* 8, 595–608. Available at:  
609 <https://onlinelibrary.wiley.com/doi/abs/10.15252/emmm.201606210> [Accessed January 5,  
610 2021].
- 611 2. Shariati, S.A.M., and De Strooper, B. (2013). Redundancy and divergence in the amyloid  
612 precursor protein family. *FEBS Lett.* 587, 2036–2045. Available at:  
613 <http://doi.wiley.com/10.1016/j.febslet.2013.05.026> [Accessed January 7, 2021].
- 614 3. Panegyres, P.K., and Atkins, E.R. (2011). The Functions of the Amyloid Precursor Protein  
615 Gene and Its Derivative Peptides: I Molecular Biology and Metabolic Processing.  
616 *Neurosci. Med.* 02, 120–131. Available at: <http://www.scirp.org/journal/nm> [Accessed  
617 January 13, 2021].
- 618 4. Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J.M., Masters, C.L., Grzeschik, K.-H.,  
619 Multhaup, G., Beyreuther, K., and Müller-Hill, B. (1987). The precursor of Alzheimer's  
620 disease amyloid A4 protein resembles a cell-surface receptor. *Nature* 325, 733–736.  
621 Available at: <http://www.nature.com/articles/325733a0> [Accessed May 10, 2019].
- 622 5. Ott, M.O., and Bullock, S.L. (2001). A gene trap insertion reveals that amyloid precursor  
623 protein expression is a very early event in murine embryogenesis. *Dev. Genes Evol.* 211,  
624 355–357. Available at: [https://link-springer-  
625 com.proxy.insermbiblio.inist.fr/article/10.1007/s004270100158](https://link-springer-com.proxy.insermbiblio.inist.fr/article/10.1007/s004270100158) [Accessed January 13,  
626 2021].
- 627 6. Sarasa, M., Sorribas, V., Terrado, J., Climent, S., Palacios, J.M., and Mengod, G. (2000).  
628 Alzheimer  $\beta$ -amyloid precursor proteins display specific patterns of expression during  
629 embryogenesis. *Mech. Dev.* 94, 233–236.
- 630 7. Salbaum, J.M., and Ruddle, F.H. (1994). Embryonic expression pattern of amyloid protein  
631 precursor suggests a role in differentiation of specific subsets of neurons. *J. Exp. Zool.*  
632 269, 116–127. Available at: [https://pubmed-ncbi-nlm-nih-  
633 gov.proxy.insermbiblio.inist.fr/8207383/](https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/8207383/) [Accessed January 13, 2021].

- 634 8. Müller, U.C., and Zheng, H. (2012). Physiological functions of APP family proteins. *Cold*  
635 *Spring Harb. Perspect. Med.* 2.
- 636 9. Coburger, I., Dahms, S.O., Roeser, D., Gührs, K.-H., Hortschansky, P., and Than, M.E.  
637 (2013). Analysis of the Overall Structure of the Multi-Domain Amyloid Precursor Protein  
638 (APP). *PLoS One* 8, e81926. Available at:  
639 <https://dx.plos.org/10.1371/journal.pone.0081926> [Accessed January 11, 2021].
- 640 10. Ninomiya, H., Roch, J.M., Sundsmo, M.P., Otero, D.A.C., and Saitoh, T. (1993). Amino  
641 acid sequence RERMS represents the active domain of amyloid  $\beta$ /A4 protein precursor  
642 that promotes fibroblast growth. *J. Cell Biol.* 121, 879–886. Available at: [https://pubmed-](https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/8491779/)  
643 [ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/8491779/](https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/8491779/) [Accessed January 13, 2021].
- 644 11. Pietrzik, C.U., Yoon, I.S., Jaeger, S., Busse, T., Weggen, S., and Koo, E.H. (2004). FE65  
645 Constitutes the Functional Link between the Low-Density Lipoprotein Receptor-Related  
646 Protein and the Amyloid Precursor Protein. *J. Neurosci.* 24, 4259–4265. Available at:  
647 <https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/15115822/> [Accessed  
648 January 13, 2021].
- 649 12. Hoe, H.S., Kea, J.L., Carney, R.S.E., Lee, J., Markova, A., Lee, J.Y., Howell, B.W.,  
650 Hyman, B.T., Pak, D.T.S., Bu, G., *et al.* (2009). Interaction of Reelin with amyloid  
651 precursor protein promotes neurite outgrowth. *J. Neurosci.* 29, 7459–7473. Available at:  
652 <https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/19515914/> [Accessed  
653 January 13, 2021].
- 654 13. Chen, C. Di, Oh, S.Y., Hinman, J.D., and Abraham, C.R. (2006). Visualization of APP  
655 dimerization and APP-Notch2 heterodimerization in living cells using bimolecular  
656 fluorescence complementation. *J. Neurochem.* 97, 30–43. Available at: [https://pubmed-](https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/16515557/)  
657 [ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/16515557/](https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/16515557/) [Accessed January 13, 2021].
- 658 14. Deyts, C., Thinakaran, G., and Parent, A.T. (2016). APP Receptor? To Be or Not to Be.  
659 *Trends Pharmacol. Sci.* 37, 390–411.
- 660 15. Hunter, S., and Brayne, C. (2012). Relationships between the amyloid precursor protein  
661 and its various proteolytic fragments and neuronal systems. *Alzheimer's Res. Ther.* 4.

- 662 16. Ayadi, A. El, Stieren, E.S., Barral, J.M., and Boehning, D. (2012). Ubiquilin-1 regulates  
663 amyloid precursor protein maturation and degradation by stimulating K63-linked  
664 polyubiquitination of lysine 688. *Proc. Natl. Acad. Sci. U. S. A.* *109*, 13416–13421.
- 665 17. Haass, C., Kaether, C., Thinakaran, G., and Sisodia, S. (2012). Trafficking and proteolytic  
666 processing of APP. *Cold Spring Harb. Perspect. Med.* *2*.
- 667 18. Yuksel, M., and Tacal, O. (2019). Trafficking and proteolytic processing of amyloid  
668 precursor protein and secretases in Alzheimer’s disease development: An up-to-date  
669 review. *Eur. J. Pharmacol.* *856*.
- 670 19. Coronel, R., Bernabeu-Zornoza, A., Palmer, C., Muñoz-Moreno, M., Zambrano, A., Cano,  
671 E., and Liste, I. (2018). Role of Amyloid Precursor Protein (APP) and Its Derivatives in  
672 the Biology and Cell Fate Specification of Neural Stem Cells. *Mol. Neurobiol.* *55*, 7107–  
673 7117. Available at: <https://doi.org/10.1007/s12035-018-0914-2> [Accessed January 13,  
674 2021].
- 675 20. Soldano, A., Okray, Z., Janovska, P., Tmejová, K., Reynaud, E., Claeys, A., Yan, J., Atak,  
676 Z.K., De Strooper, B., Dura, J.-M., *et al.* (2013). The Drosophila Homologue of the  
677 Amyloid Precursor Protein Is a Conserved Modulator of Wnt PCP Signaling. *PLoS Biol.*  
678 *11*, e1001562. Available at: <https://dx.plos.org/10.1371/journal.pbio.1001562> [Accessed  
679 April 24, 2019].
- 680 21. Oishi, I., Suzuki, H., Onishi, N., Takada, R., Kani, S., Ohkawara, B., Koshida, I., Suzuki,  
681 K., Yamada, G., Schwabe, G.C., *et al.* (2003). The receptor tyrosine kinase Ror2 is  
682 involved in non-canonical Wnt5a/JNK signalling pathway. *Genes to Cells* *8*, 645–654.  
683 Available at: [https://onlinelibrary-wiley-](https://onlinelibrary-wiley-com.proxy.insermbiblio.inist.fr/doi/full/10.1046/j.1365-2443.2003.00662.x)  
684 [com.proxy.insermbiblio.inist.fr/doi/full/10.1046/j.1365-2443.2003.00662.x](https://onlinelibrary-wiley-com.proxy.insermbiblio.inist.fr/doi/full/10.1046/j.1365-2443.2003.00662.x) [Accessed  
685 January 13, 2021].
- 686 22. Eisenmann, D.M. (2005). Wnt signaling. *WormBook*, 1–17. Available at: [https://pubmed-](https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/18050402/)  
687 [ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/18050402/](https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/18050402/) [Accessed January 13, 2021].
- 688 23. Sellers, K.J., Elliott, C., Jackson, J., Ghosh, A., Ribe, E., Rojo, A.I., Jarosz-Griffiths,  
689 H.H., Watson, I.A., Xia, W., Semenov, M., *et al.* (2018). Amyloid  $\beta$  synaptotoxicity is

- 690 Wnt-PCP dependent and blocked by fasudil. *Alzheimer's Dement.* *14*, 306–317. Available  
691 at: <https://www.sciencedirect.com/science/article/pii/S1552526017337627> [Accessed  
692 April 1, 2019].
- 693 24. Elliott, C., Rojo, A.I., Ribe, E., Broadstock, M., Xia, W., Morin, P., Semenov, M., Baillie,  
694 G., Cuadrado, A., Al-Shawi, R., *et al.* (2018). A role for APP in Wnt signalling links  
695 synapse loss with  $\beta$ -amyloid production. *Transl. Psychiatry* *8*, 179. Available at:  
696 <http://www.nature.com/articles/s41398-018-0231-6> [Accessed April 1, 2019].
- 697 25. Cassar, M., and Kretzschmar, D. (2016). Analysis of amyloid precursor protein function in  
698 *Drosophila melanogaster*. *Front. Mol. Neurosci.* *9*, 61.
- 699 26. Nicolas, M., and Hassan, B.A. (2014). Amyloid precursor protein and neural  
700 development. *Dev.* *141*, 2543–2548.
- 701 27. Preat, T., and Goguel, V. (2016). Role of *Drosophila* amyloid precursor protein in  
702 memory formation. *Front. Mol. Neurosci.* *9*, 142.
- 703 28. Soldano, A., and Hassan, B.A. (2014). Beyond pathology: APP, brain development and  
704 Alzheimer's disease. *Curr. Opin. Neurobiol.* *27*, 61–67.
- 705 29. van der Kant, R., and Goldstein, L.S.B. (2015). Cellular Functions of the Amyloid  
706 Precursor Protein from Development to Dementia. *Dev. Cell* *32*, 502–515.
- 707 30. Heisenberg, M. (2003). Mushroom body memoir: From maps to models. *Nat. Rev.*  
708 *Neurosci.* *4*, 266–275.
- 709 31. Shimizu, K., Sato, M., and Tabata, T. (2011). The Wnt5/planar cell polarity pathway  
710 regulates axonal development of the *Drosophila* mushroom body neuron. *J. Neurosci.* *31*,  
711 4944–4954.
- 712 32. Grillenzoni, N., Flandre, A., Lasbleiz, C., and Dural, J.M. (2007). Respective roles of the  
713 DRL receptor and its ligand WNT5 in *Drosophila* mushroom body development.  
714 *Development* *134*, 3089–3097.



- 715 33. Dann, C.E., Hsieh, J.C., Rattner, A., Sharma, D., Nathans, J., and Leahy, D.J. (2001).  
716 Insights into Wnt binding and signalling from the structures of two Frizzled cysteine-rich  
717 domains. *Nature* 412, 86–90.
- 718 34. Oishi, I., Suzuki, H., Onishi, N., Takada, R., Kani, S., Ohkawara, B., Koshida, I., Suzuki,  
719 K., Yamada, G., Schwabe, G.C., *et al.* (2003). The receptor tyrosine kinase Ror2 is  
720 involved in non-canonical Wnt5a/JNK signalling pathway. *Genes to Cells* 8, 645–654.  
721 Available at: <http://doi.wiley.com/10.1046/j.1365-2443.2003.00662.x> [Accessed February  
722 18, 2020].
- 723 35. Bush, A.I., Multhaup, G., Moir, R.D., Williamson, T.G., Small, D.H., Rumble, B.,  
724 Pollwein, P., Beyreuther, K., and Masters, C.L. (1993). A novel zinc(II) binding site  
725 modulates the function of the  $\beta$ A4 amyloid protein precursor of Alzheimer's disease. *J.*  
726 *Biol. Chem.* 268, 16109–16112.
- 727 36. Ayadi, A. El, Stieren, E.S., Barral, J.M., and Boehning, D. (2012). Ubiquilin-1 regulates  
728 amyloid precursor protein maturation and degradation by stimulating K63-linked  
729 polyubiquitination of lysine 688. *Proc. Natl. Acad. Sci. U. S. A.* 109, 13416–13421.
- 730 37. Hunter, S., and Brayne, C. (2012). Relationships between the amyloid precursor protein  
731 and its various proteolytic fragments and neuronal systems. *Alzheimer's Res. Ther.* 4.
- 732 38. Vagnozzi, A.N., and Praticò, D. (2019). Endosomal sorting and trafficking, the retromer  
733 complex and neurodegeneration. *Mol. Psychiatry* 24, 857–868.
- 734 39. Mulligan, K.A., and Cheyette, B.N.R. (2012). Wnt signaling in vertebrate neural  
735 development and function. *J. Neuroimmune Pharmacol.* 7, 774–787.
- 736 40. Rosso, S.B., and Inestrosa, N.C. (2013). WNT signalling in neuronal maturation and  
737 synaptogenesis. *Front. Cell. Neurosci.* 7.
- 738 41. Parr, C., Mirzaei, N., Christian, M., and Sastre, M. (2015). Activation of the Wnt/ $\beta$ -  
739 catenin pathway represses the transcription of the  $\beta$ -amyloid precursor protein cleaving  
740 enzyme (BACE1) via binding of T-cell factor-4 to BACE1 promoter. *FASEB J.* 29, 623–  
741 635.

- 742 42. Tapia-Rojas, C., Burgos, P. V., and Inestrosa, N.C. (2016). Inhibition of Wnt signaling  
743 induces amyloidogenic processing of amyloid precursor protein and the production and  
744 aggregation of Amyloid- $\beta$  (A $\beta$ )<sub>42</sub> peptides. *J. Neurochem.* *139*, 1175–1191.
- 745 43. Billnitzer, A.J., Barskaya, I., Yin, C., and Perez, R.G. (2013). APP independent and  
746 dependent effects on neurite outgrowth are modulated by the receptor associated protein  
747 (RAP). *J. Neurochem.*
- 748 44. Young-Pearse, T.L., Chen, A.C., Chang, R., Marquez, C., and Selkoe, D.J. (2008).  
749 Secreted APP regulates the function of full-length APP in neurite outgrowth through  
750 interaction with integrin beta1. *Neural Dev.* *3*. Available at: [https://pubmed.ncbi.nlm.nih-](https://pubmed.ncbi.nlm.nih.gov.proxy.insermbiblio.inist.fr/18573216/)  
751 [gov.proxy.insermbiblio.inist.fr/18573216/](https://pubmed.ncbi.nlm.nih.gov.proxy.insermbiblio.inist.fr/18573216/) [Accessed September 8, 2020].
- 752 45. Dotti, C.G., Sullivan, C.A., and Banker, G.A. (1988). The establishment of polarity by  
753 hippocampal neurons in culture. *J. Neurosci.* *8*, 1454–1468.
- 754 46. Wong, H.H.W., Lin, J.Q., Ströhl, F., Roque, C.G., Cioni, J.M., Cagnetta, R., Turner-  
755 Bridger, B., Laine, R.F., Harris, W.A., Kaminski, C.F., *et al.* (2017). RNA Docking and  
756 Local Translation Regulate Site-Specific Axon Remodeling In Vivo. *Neuron* *95*, 852-  
757 868.e8.
- 758 47. Polleux, F., and Snider, W. (2010). Initiating and growing an axon. *Cold Spring Harb.*  
759 *Perspect. Biol.* *2*.
- 760 48. Barnes, A.P., and Polleux, F. (2009). Establishment of axon-dendrite polarity in  
761 developing neurons. *Annu. Rev. Neurosci.* *32*, 347–81. Available at:  
762 <http://www.ncbi.nlm.nih.gov/pubmed/19400726> [Accessed June 10, 2020].
- 763 49. Araki, W., Kitaguchi, N., Tokushima, Y., Ishii, K., Aratake, H., Shimohama, S.,  
764 Nakamura, S., and Kimura, J. (1991). Trophic effect of  $\beta$ -amyloid precursor protein on  
765 cerebral cortical neurons in culture. *Biochem. Biophys. Res. Commun.* *181*, 265–271.
- 766 50. Southam, K.A., Stennard, F., Pavez, C., and Small, D.H. (2019). Knockout of Amyloid  $\beta$   
767 Protein Precursor (APP) Expression Alters Synaptogenesis, Neurite Branching and  
768 Axonal Morphology of Hippocampal Neurons. *Neurochem. Res.* *44*, 1346–1355.

- 769 Available at: <https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/29572646/>  
770 [Accessed July 15, 2020].
- 771 51. Small, D.H., Nurcombe, V., Reed, G., Clarris, H., Moir, R., Beyreuther, K., and Masters,  
772 C.L. (1994). A heparin-binding domain in the amyloid protein precursor of Alzheimer's  
773 disease is involved in the regulation of neurite outgrowth. *J. Neurosci.* *14*, 2117–2127.  
774 Available at: <https://www-jneurosci-org.proxy.insermbiblio.inist.fr/content/14/4/2117>  
775 [Accessed September 3, 2020].
- 776 52. Perez, R.G., Zheng, H., Van Der Ploeg, L.H.T., and Koo, E.H. (1997). The  $\beta$ -amyloid  
777 precursor protein of Alzheimer's disease enhances neuron viability and modulates  
778 neuronal polarity. *J. Neurosci.* *17*, 9407–9414. Available at: [https://www-jneurosci-](https://www-jneurosci-org.proxy.insermbiblio.inist.fr/content/17/24/9407)  
779 [org.proxy.insermbiblio.inist.fr/content/17/24/9407](https://www-jneurosci-org.proxy.insermbiblio.inist.fr/content/17/24/9407) [Accessed September 4, 2020].
- 780 53. Cheng, A., Yang, Y., Zhou, Y., Maharana, C., Lu, D., Peng, W., Liu, Y., Wan, R., Marosi,  
781 K., Misiak, M., *et al.* (2016). Mitochondrial SIRT3 Mediates Adaptive Responses of  
782 Neurons to Exercise and Metabolic and Excitatory Challenges. *Cell Metab.* *23*, 128–142.
- 783 54. Liu, T., Zhang, T., Yu, H., Shen, H., and Xia, W. (2014). Adjudin protects against cerebral  
784 ischemia reperfusion injury by inhibition of neuroinflammation and blood-brain barrier  
785 disruption. *J. Neuroinflammation* *11*.
- 786 55. Bolte, S., and Cordelières, F.P. (2006). A guided tour into subcellular colocalization  
787 analysis in light microscopy. *J. Microsc.* *224*, 213–232. Available at:  
788 <https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2818.2006.01706.x> [Accessed  
789 January 13, 2021].

790